Characterizing smoking topography of cannabis in heavy users.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Behavior, Addictive*; Marijuana Abuse/*physiopathology ; Marijuana Abuse/*psychology ; Marijuana Smoking/*physiopathology ; Marijuana Smoking/*psychology; Adolescent ; Adult ; Cognition/drug effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Psychiatric Status Rating Scales/statistics & numerical data ; Psychomotor Performance/drug effects ; Sleep/drug effects ; Substance Withdrawal Syndrome/diagnosis ; Substance Withdrawal Syndrome/psychology

Rationale: Little is known about the smoking topography characteristics of heavy cannabis users. Such measures may be able to predict cannabis use-related outcomes and could be used to validate self-reported measures of cannabis use.
Objectives: The current study was conducted to measure cannabis smoking topography characteristics during periods of ad libitum use and to correlate topography assessments with measures of self-reported cannabis use, withdrawal and craving during abstinence, and cognitive task performance.
Methods: Participants (N = 20) completed an inpatient study in which they alternated between periods of ad libitum cannabis use and abstinence. Measures of self-reported cannabis use, smoking topography, craving, withdrawal, and sleep measures were collected.
Results: Participants smoked with greater intensity (e.g., greater volume, longer duration) on initial cigarette puffs with a steady decline on subsequent puffs. Smoking characteristics were significantly correlated with severity of withdrawal, notably sleep quality and architecture, and craving during abstinence, suggesting dose-related effects of cannabis use on these outcomes. Smoking characteristics generally were not significantly associated with cognitive performance. Smoking topography measures were significantly correlated with self-reported measures of cannabis use, indicating validity of these assessments, but topography measures were more sensitive than self-report in predicting cannabis-related outcomes.
Conclusions: A dose-effect relationship between cannabis consumption and outcomes believed to be clinically important was observed. With additional research, smoking topography assessments may become a useful clinical tool.

J Pharmacol Exp Ther. 1995 Feb;272(2):560-9. (PMID: 7853169)
Drug Alcohol Depend. 2011 Aug 1;117(1):38-44. (PMID: 21296508)
Pharmacol Biochem Behav. 1991 Nov;40(3):651-6. (PMID: 1666923)
Drug Alcohol Depend. 1985 May;15(1-2):1-13. (PMID: 4017866)
Addict Behav. 2004 Jun;29(4):699-706. (PMID: 15135551)
Addict Behav. 1983;8(2):115-9. (PMID: 6613709)
Compr Psychiatry. 1993 Nov-Dec;34(6):375-83. (PMID: 8131381)
Am J Addict. 2009 Mar-Apr;18(2):178-9. (PMID: 19283572)
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):154-7. (PMID: 16434603)
J Subst Abuse Treat. 2008 Dec;35(4):362-8. (PMID: 18342479)
Psychiatry Res. 1989 May;28(2):193-213. (PMID: 2748771)
Electroencephalogr Clin Neurophysiol. 1993 Sep;87(3):128-43. (PMID: 7691540)
Psychopharmacology (Berl). 1991;103(2):223-6. (PMID: 2027922)
Am J Addict. 2006 Jan-Feb;15(1):8-14. (PMID: 16449088)
Drug Alcohol Depend. 2011 Jan 15;113(2-3):249-51. (PMID: 20863627)
Nicotine Tob Res. 2010 Feb;12(2):164-7. (PMID: 19969556)
J Clin Pharmacol. 1981 Aug-Sep;21(S1):201S-207S. (PMID: 6271825)
Addiction. 1999 Sep;94(9):1311-22. (PMID: 10615717)
Behav Pharmacol. 1997 Nov;8(6-7):561-74. (PMID: 9832970)
Clin Pharmacol Ther. 1982 May;31(5):617-24. (PMID: 6280918)
Am Rev Respir Dis. 1977 Jan;115(1):57-65. (PMID: 319717)
Clin Pharmacokinet. 2003;42(4):327-60. (PMID: 12648025)
Pharmacol Biochem Behav. 1989 Sep;34(1):173-9. (PMID: 2560548)
Physiol Rev. 1952 Jul;32(3):349-78. (PMID: 12983227)
J Psychoactive Drugs. 1988 Jan-Mar;20(1):43-6. (PMID: 2839655)
Behav Pharmacol. 1993 Apr;4(2):167-178. (PMID: 11224183)
Life Sci. 1995;56(23-24):2185-91. (PMID: 7776848)
Arch Gen Psychiatry. 2001 Oct;58(10):909-15. (PMID: 11576028)
J Adolesc Health. 2011 Feb;48(2):176-81. (PMID: 21257117)
Exp Clin Psychopharmacol. 2010 Feb;18(1):1-16. (PMID: 20158290)
Subst Use Misuse. 2009;44(3):401-15. (PMID: 19212929)
Neuropsychopharmacology. 2006 Oct;31(10):2296-303. (PMID: 16572123)
Philos Trans R Soc Lond B Biol Sci. 1982 Jun 25;298(1089):199-209. (PMID: 6125971)
Drug Alcohol Depend. 2007 Jan 12;86(2-3):294-300. (PMID: 16930853)
Addict Behav. 2008 Nov;33(11):1500-1505. (PMID: 18313860)
Pharmacol Biochem Behav. 1986 Sep;25(3):659-65. (PMID: 3774833)
Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1370-5. (PMID: 15941943)
Drug Alcohol Depend. 2009 Jun 1;102(1-3):35-40. (PMID: 19217724)
Pharmacol Biochem Behav. 1989 May;33(1):189-95. (PMID: 2780776)
Pharmacol Biochem Behav. 1989 Jun;33(2):481-4. (PMID: 2554344)
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1800-4. (PMID: 15533910)
Pharmacol Biochem Behav. 1991 Nov;40(3):657-61. (PMID: 1666924)
Addiction. 1993 Jun;88(6):821-30. (PMID: 8329973)
N Engl J Med. 1988 Feb 11;318(6):347-51. (PMID: 3340105)
Pharmacol Biochem Behav. 1992 Apr;41(4):701-6. (PMID: 1594637)
Curr Psychiatry Rep. 2001 Dec;3(6):507-12. (PMID: 11707165)
Drug Alcohol Depend. 2010 Jan 15;106(2-3):111-8. (PMID: 19783385)

R21 DA025794 United States DA NIDA NIH HHS; T32 DA007209 United States DA NIDA NIH HHS; R21-DA025794 United States DA NIDA NIH HHS; T32-DA07209 United States DA NIDA NIH HHS

Date Created: 20110917 Date Completed: 20120727 Latest Revision: 20211020

20240829

PMC3641906

10.1007/s00213-011-2480-4

21922170